Electromedical Technologies Announces on boarding of
In-House Biophysicist to work with Nazarbayev University in
Studying the Effects of Electrical Frequencies on Cell
Signaling
SCOTTSDALE, AZ -- September 11,
2020 -- InvestorsHub NewsWire -- Electromedical Technologies, Inc.
(OTCMKTS:EMED)
(the "Company"), a pioneer in the development and manufacturing of
bioelectronic devices, is pleased to announce the hiring of
Dr Rakhim Bulibekov as in-house biophysicist
to work directly with Nazarbayev University, Nur-Sultan,
Kazakhstan, in the development of a comprehensive research program
to study effects of electro-modulation on the insulin-dependent
glucose uptake, pro-inflammatory or stress-dependent cytokine
secretion, hypertension, tumor growth and viral infection in
mammalian animal models. Regulation of the physiological responses
by electro-modulation will provide a leverage for corrections of
disease related physiological defects.
The proposed Phase I studies in
the animal models will serve to lay a foundation for clinical
applications of electro-modulation in a coming Phase II research and
development program.
Mr. Bulibekov will be the liaison between
Electromedical Technologies, Inc and Dr. Dos Sarbassov, Professor
of the Department of Biology, School of Sciences and Humanities at
Nazarbayev University. Having an in-house biophysicist allows for
an enhanced understanding of the progress in the study as it
unfolds and a guiding hand in the implementation of the research
program, including its timeline, on a day to day basis. Dr
Bulibekov
will help to ensure
time efficiency and quality in executing this important
research.
Matthew Wolfson, Founder and
CEO of Electromedical Technologies, commented, "Dr
Bulibekov
is a tremendous
asset to have on board as we kick off what promises to be powerful
research with the potential to drive compelling advances in our
understanding of alternating electrical fields, cell signaling,
electro-modulation, and the cellular context."
Dr. Bulibekov was educated at the prestigious
Kazakh National University, where he was later a researcher in
bio-medical technology. He was also a key figure at the Academy of
Health in the Republic of Kazakhstan. Before that, he was at the
Academy of Science in Kazakhstan, where he was involved at the
Institute of Nuclear Physics in research on radiation and
electroactivity of cells.
Dr. Bulibekov added, "I look forward to
making important contributions on this critical study. Cellular
signaling and electroactivity holds enormous
promise not only for the treatment of chronic pain, but for so many
potential future applications now of tremendous interest in the
field of Bioelectronics."
About
Nazarbayev University
Nazarbayev University (NU),
established on the initiative of the first President of the
Republic of Kazakhstan in 2010, is the country's flagship academic
institution with aspirations to become a global-level research
university. This is the first university in Kazakhstan which is
guided by the principles of autonomy and academic freedom. Located
in the capital of Kazakhstan, NU is a research university with
growing international renown combining education, research and
innovation on a state of the art 21st-century campus. NU scholars
conduct research in many fields, and seek to expand human knowledge
through innovation, analysis, and collaboration. Within ten years
since its inception, NU has become a leading research university in
Kazakhstan. NU research is supported by the government of the
Republic of Kazakhstan, local and international organizations, and
is carried out in the Schools, Research Centers and Institutes.
Please visit Nazarbayev University website https://research.nu.edu.kz/en/ to find comprehensive
information on the NU research activities and profiles of faculty
and researchers.
About
Electromedical Technologies
Headquartered in Scottsdale
Arizona, Electromedical Technologies, Inc. is a commercial stage,
FDA cleared, bioelectronic medical device manufacturing company
initially focused on the treatment of various chronic, acute,
intractable, and post-operative pain
conditions. Through university collaboration agreements the company
is working to develop a comprehensive research program in defining
the effects of electro-modulation on the human body by studying the
impacts of electrical fields in cell signaling and effects on virus
assembly and immune responses with the goal of improving human
wellbeing. The company's current cleared product indications are
for chronic acute post traumatic and post-operative, intractable
pain relief.
Our animal studies do not
involve any human testing, and are not related to our current
products. We are conducting this research to augment and advance
the science of electro-modulation in healthcare. The United
States Food and Drug Administration has not reviewed or approved
our animal research studies
For more information,
visit www.electromedtech.com.
Safe Harbor
Statement
This release contains
forward-looking statements that are based upon current expectations
or beliefs, as well as a number of assumptions about future events.
Although we believe that the expectations reflected in the
forward-looking statements and the assumptions upon which they are
based are reasonable, we can give no assurance or guarantee that
such expectations and assumptions will prove to have been correct.
Forward-looking statements are generally identifiable by the use of
words like "may," "will," "should," "could," "expect,"
"anticipate," "estimate," "believe," "intend," or "project" or the
negative of these words or other variations on these words or
comparable terminology. The reader is cautioned not to put undue
reliance on these forward-looking statements, as these statements
are subject to numerous factors and uncertainties, including but
not limited to: adverse economic conditions, competition, adverse
federal, state and local government regulation, international
governmental regulation, inadequate capital, inability to carry out
research, development and commercialization plans, loss or
retirement of key executives and other specific risks. To the
extent that statements in this press release are not strictly
historical, including statements as to revenue projections,
business strategy, outlook, objectives, future milestones, plans,
intentions, goals, future financial conditions, events conditioned
on stockholder or other approval, or otherwise as to future events,
such statements are forward-looking, and are made pursuant to the
safe harbor provisions of the Private Securities Litigation Reform
Act of 1995. The forward-looking statements contained in this
release are subject to certain risks and uncertainties that could
cause actual results to differ materially from the statements
made.
Corporate
Contact:
Electromedical Technologies,
Inc.
Matthew
Wolfson
Tel:
1.888.880.7888
email:
ceo@electromedtech.com
https://electromedtech.com
Public
Relations Contact:
Tiger Global Marketing &
Branding Agency
info@TigerGMP.com
www.TigerGMP.com